Collision Tumour of Combined Neuroendocrine and Squamous Cell Carcinoma of Nasal Cavity and Paranasal Sinus- Case Report and Review of Literature

Vikas Arora; Vishal Yadav; Manisha Aggarwal; Ghanashyam Mandal; Arnab Chakraborty; A K Dewan; Meenakshi Kamboj

doi:10.1007/s12070-023-04101-9

Collision Tumour of Combined Neuroendocrine and Squamous Cell Carcinoma of Nasal Cavity and Paranasal Sinus- Case Report and Review of Literature

Indian J Otolaryngol Head Neck Surg. 2023 Dec;75(4):3765-3769. doi: 10.1007/s12070-023-04101-9. Epub 2023 Jul 21.

Authors

Vikas Arora¹, Vishal Yadav¹, Manisha Aggarwal¹, Ghanashyam Mandal¹, Arnab Chakraborty¹, A K Dewan¹, Meenakshi Kamboj²

Affiliations

¹ Department of Head and Neck Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, 110085 India.
² Department of Patho Oncology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, 110085 India.

PMID: 37974826
PMCID: PMC10646142 (available on 2024-12-01)
DOI: 10.1007/s12070-023-04101-9

Abstract

Background: There have been many disputes about the definition, diagnosis, therapy, and prognosis of collision tumours.

Case summary: We describe a rare patient with a collision tumour consisting of high-grade neuroendocrine carcinoma (NEC) and squamous cell carcinoma (SCC) in the right nasal cavity and paranasal sinus. She received surgery, concurrent chemoradiotherapy, and then two cycles of palliative chemotherapy. Follow-up at 26 months after diagnosis showed that this patient experienced a complete response with no signs of recurrence or metastasis. A literature review of previous 27 cases diagnosed with collision tumour of NEC and SCC in the head and neck was also undertaken.

Conclusion: It is highly challenging to manage collision tumours because these are two morphologically and etiologically distinct tumours. Well-designed multimodality therapy including surgery and chemoradiotherapy might lead to a long survival in these patients.

Keywords: Case Report; Chemoradiotherapy; Collision Tumour; Head and Neck; High Grade Neuroendocrine Carcinoma; Squamous Cell Carcinoma.

© Association of Otolaryngologists of India 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.